XTL Biopharmaceuticals Ltd ADR Cash Flow Conversion Efficiency
XTL Biopharmaceuticals Ltd ADR cash flow conversion efficiency. Based on the latest financial reports, XTL Biopharmaceuticals Ltd ADR (XTLB) has a cash flow conversion efficiency ratio of -0.502x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.01 Million) by net assets ($4.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of XTL Biopharmaceuticals Ltd ADR (2003–2025)
Cash flow conversion efficiency of XTL Biopharmaceuticals Ltd ADR from 2003 to 2025. This chart illustrates how XTL Biopharmaceuticals Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View XTLB live share price for real-time trading data and today's change.
XTL Biopharmaceuticals Ltd ADR Cash Flow Conversion Ratio Explained
XTL Biopharmaceuticals Ltd ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
XTL Biopharmaceuticals Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XTL Biopharmaceuticals Ltd ADR ranked by their cash flow conversion efficiency. Also see XTLB market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SOLUTIANCE AG NA O.N.
F:SLSA
|
N/A |
|
CS Corporation
KQ:065770
|
-0.030x |
|
Reliance Chemotex Industries Limited
NSE:RELCHEMQ
|
0.161x |
|
Bermas SA
RO:BRM
|
N/A |
|
Equus Total Return Closed Fund
NYSE:EQS
|
0.000x |
|
NEXE Innovations Inc
V:NEXE
|
-0.026x |
|
Niobay Metals Inc
V:NBY
|
-0.432x |
|
João Fortes Engenharia S.A.
SA:JFEN3
|
0.152x |
Annual Cash Flow Conversion Efficiency for XTL Biopharmaceuticals Ltd ADR (2003–2025)
The table below shows the annual cash flow conversion efficiency of XTL Biopharmaceuticals Ltd ADR from 2003 to 2025. Review XTL Biopharmaceuticals Ltd ADR free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-254.00K | $-1.02 Million | 4.035x | +1455.54% |
| 2024-12-31 | $5.43 Million | $-1.62 Million | -0.298x | +6.52% |
| 2023-12-31 | $2.22 Million | $-707.00K | -0.318x | -41.35% |
| 2022-12-31 | $4.00 Million | $-901.00K | -0.225x | -14.54% |
| 2021-12-31 | $5.33 Million | $-1.05 Million | -0.197x | -44.61% |
| 2020-12-31 | $6.25 Million | $-850.00K | -0.136x | -4.56% |
| 2019-12-31 | $6.98 Million | $-908.00K | -0.130x | -32.67% |
| 2018-12-31 | $8.32 Million | $-816.00K | -0.098x | +68.46% |
| 2017-12-31 | $3.62 Million | $-1.12 Million | -0.311x | +51.77% |
| 2016-12-31 | $2.69 Million | $-1.73 Million | -0.645x | -69.27% |
| 2015-12-31 | $4.89 Million | $-1.86 Million | -0.381x | +27.86% |
| 2014-12-31 | $4.68 Million | $-2.47 Million | -0.528x | -43.33% |
| 2013-12-31 | $6.79 Million | $-2.50 Million | -0.368x | -130.48% |
| 2012-12-31 | $9.42 Million | $-1.51 Million | -0.160x | +69.44% |
| 2011-12-31 | $3.44 Million | $-1.80 Million | -0.523x | -101.63% |
| 2010-12-31 | $2.83 Million | $-735.00K | -0.259x | +99.93% |
| 2009-12-31 | $7.00K | $-2.49 Million | -355.429x | -4691.46% |
| 2008-12-31 | $1.43 Million | $-10.58 Million | -7.418x | -196.07% |
| 2007-12-31 | $8.56 Million | $-21.46 Million | -2.505x | -353.05% |
| 2006-12-31 | $22.76 Million | $-12.59 Million | -0.553x | +40.54% |
| 2005-12-31 | $11.25 Million | $-10.47 Million | -0.930x | -25.79% |
| 2004-12-31 | $19.60 Million | $-14.49 Million | -0.739x | -14.35% |
| 2003-12-31 | $20.61 Million | $-13.33 Million | -0.647x | -- |
About XTL Biopharmaceuticals Ltd ADR
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more